Genetron Holdings Limited
(“Genetron Health” or the “Company”) (Nasdaq: GTH) is a world-leading precision oncology platform
company that specializes in research and application of cancer genomics, providing early
screening, medication guidance, prognostic monitoring, and new cancer drug development services
that cover the entire spectrum of cancer management. The company is committed to applying
innovative genomics technology to cancer-related diagnosis and treatment, and ultimately defeating
CHARLES DARWIN—THE FATHER OF EVOLUTION—PROPOSED THE THEORY OF PANGENESIS, WHICH LAID THE FOUNDATION
MODERN GENETICS AND HELPED COIN THE TERM ‘PANGENE’. IN CHINESE, PANGENE IS 泛生子.
AN ONCOLOGY PLATFORM FOR TRANSFORMING CARE
DIAGNOSTICS & MONITORING
THE GENETRON PLATFORM
At Genetron, we firmly believe in using the best tools that science and technology has to offer
for our work, and we hold ourselves to the most rigorous of international standards. From academic
research to laboratory operations, precision insights require consistent and thorough processes.
Each patient’s journey through
cancer is a fiercely personal experience. Whether it’s targeted treatment, continuous monitoring,
or actionable guidance, Genetron’s precision solutions are crafted with an emphasis on
personalization and participation—for patients and partners alike.
Breakthrough innovations and the transformations they catalyze are enabled by a zeal for life and
empathy for people. Genetron’s core values (B.R.A.V.E.) foster a culture that empowers each of us
to navigate ambiguity and discover solutions anchored by the needs of those we serve.